nach oben

Drugs & Aging

Erschienen in:

01.04.2013 | Review Article

Bronchiectasis in Older Patients with Chronic Obstructive Pulmonary Disease

Prevalence, Diagnosis and Therapeutic Management

verfasst von: Deborah Whitters, Robert A. Stockley

Erschienen in: Drugs & Aging | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

The prevalence of chronic obstructive pulmonary disease (COPD) increases with age. Recent evidence suggests that the finding of co-existent bronchiectasis is becoming increasingly common, possibly because of increased use of high-resolution CT scanning in the assessment of patients with COPD. This may represent a distinct phenotype of COPD, but, nevertheless, it is likely to pose an increased burden to health services and challenges in determining the correct management of these patients. Here, we review the factors associated with bronchiectasis in older patients with COPD and the evidence for many of the therapies currently used in the treatment of patients, providing a rational approach to their management.

Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–9.CrossRef

Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3):523–32.PubMedCrossRef

O’Brien C, Guest PJ, Hill SL, et al. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55:635–42.PubMedCrossRef

Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130–7.PubMedCrossRef

Cole P, Wilson R. Host microbial interrelationships in respiratory infection. Chest. 1989;95:217S–21S.CrossRef

Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000;162:1277–84.PubMedCrossRef

Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guidelines for non CF bronchiectasis. Thorax. 2010;65:i1–58.PubMedCrossRef

O’Donnell AE. Bronchiectasis in patients with COPD: a distinct COPD phenotype? Chest. 2011;140(5):1107–8.PubMedCrossRef

Wedzicha JA, Hurst JR. Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. Proc Am Thor Soc. 2007;4(8):602–5.CrossRef

10.

Devereux G. ABC of chronic obstructive pulmonary disease. Definition, epidemiology and risk factors. BMJ. 2006;332:1142–4.PubMedCrossRef

11.

Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.PubMed

12.

Patel IS, Vlahos I, Wilkinson TMA, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400–7.PubMedCrossRef

13.

Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(5 Suppl):121S–6S.PubMedCrossRef

14.

Murray CJL, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science. 1996;274(5288):740–3.PubMedCrossRef

15.

Crofton J, Douglas A, editors. Respiratory diseases. 3rd ed. Oxford: Blackwell Science Ltd; 1981. p. 417–30.

16.

Saynajakangas O, Keistinen T, Tuuponen T, et al. Bronchiectasis in Finland: trends in hospital treatment. Respir Med. 1997;91(7):395–8.PubMedCrossRef

17.

Roberts HJ, Hubbard R. Trends in bronchiectasis mortality in England and Wales. Resp Med. 2010;104(7):981–5.CrossRef

18.

Seitz AE, Olivier KN, Steiner CA, et al. Trends and burden of bronchiectasis-associated hospitalisations in the United States, 1993–2006. Chest. 2010;138(4):944–9.PubMedCrossRef

19.

Smith IE, Jurriaans E, Diederich S, et al. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax. 1996;51(9):914–8.PubMedCrossRef

20.

Jones DK, Godden D, Cavanage P. Alpha 1 antitrypsin deficiency presenting as bronchiectasis. Br J Dis Chest. 1985;79(3):301–4.PubMedCrossRef

21.

Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiological, radiologic, and health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). Chest. 2002;122(4):1247–55.PubMedCrossRef

22.

Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2007;176(12):1215–21.PubMedCrossRef

23.

Stockley RA, O’Brien C, Pye A, et al. Relationship of sputum colour to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–45.PubMedCrossRef

24.

Wilson R. Bacteria, antibiotics and COPD. Eur Resp J. 2001;17(5):995–1007.CrossRef

25.

Murphy TF, Brauer AL, Eschberger K, et al. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):853–60.PubMedCrossRef

26.

Martinez-Garcia MA, Soler-Cataluńa JJ, Perpińá-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565–72.PubMedCrossRef

27.

Wilson R. Outcome predictors in bronchitis. Chest. 1995;108(2):53s–7s.PubMedCrossRef

28.

Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis. 1993;147(2):301–6.PubMedCrossRef

29.

Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis cellular and molecular mechanisms. Eur Respir J. 2008;31(2):396–406.PubMedCrossRef

30.

Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc. 2008;5(4):475–7.PubMedCrossRef

31.

Cole PJ. Inflammation: a two edged sword – the model of bronchiectasis. Eur J. Respir Dis Suppl. 1986;147:6–15.PubMed

32.

Martinez Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Quality of life determinants in patients with clinically stable bronchiectasis. Chest. 2005;128(2):739–45.PubMedCrossRef

33.

Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax. 2000;55(3):198–204.PubMedCrossRef

34.

King P, Holdsworth SR, Freezer NJ, et al. Outcome in adult bronchiectasis. COPD. 2005;2(1):27–34.PubMedCrossRef

35.

King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411–9.PubMedCrossRef

36.

Elborn JS, Johnstone B, Allen F, et al. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86(2):121–4.PubMedCrossRef

37.

Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a twelve month study. Thorax. 2005;60(3):239–43.PubMedCrossRef

38.

Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100(9):1623–32.PubMedCrossRef

39.

Sheikh A, Nolan D, Greenstone M. Long-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2001;(4):CD002155.

40.

Franco F, Sheikh A, Greenstone M. Short-acting beta-2-agonists for bronchiectasis. Cochrane Database Syst Rev. 2003;(3):CD003572.

41.

Tashkin DP, Celli B, Senn S, et al. A four year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.PubMedCrossRef

42.

Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991–8.PubMedCrossRef

43.

Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001;164(9):1628–32.PubMedCrossRef

44.

King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs. 2007;67(7):965–74.PubMedCrossRef

45.

Sin DD, Man SF. Steroids in COPD: still up in the air? Eur Respir J. 2010;35(5):949–51.PubMedCrossRef

46.

Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–7.PubMedCrossRef

47.

Singh S, Loke YK. Risk of pneumonia associated with long term use of inhaled corticosteroids in COPD: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118–22.PubMedCrossRef

48.

Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Resp Crit Care Med. 2008;177(1):19–26.PubMedCrossRef

49.

National Institute for Health and Clinical Excellence. Clinical guideline 101 – chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care (update of NICE clinical guideline 12). London: National Institute for Health and Clinical Excellence. June 2010. http://guidance.nice.org.uk/CG101. Accessed 17 Sep 2012.

50.

Kapur N, Bell S, Kolbe J et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; 21(1):CD000996.

51.

Tsang KW, Pak-Leung HO, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158(3):723–7.PubMedCrossRef

52.

Martinez-Garcia MA, Soler-Cataluna JJ, Catalan-Serra P, et al. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012;141(2):461–8.PubMedCrossRef

53.

Antoniu SA. New therapeutic options in the management of COPD – focus on roflumilast. Int J Chron Obstruct Pulmon Dis. 2011;6:147–55.PubMedCrossRef

54.

Gamble E, Grootendorst DC, Brightling CE, et al. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(8):967–82.CrossRef

55.

Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.PubMedCrossRef

56.

Foreman MG, DeMeo DL, Hersh CP, et al. Clinical determinants of exacerbations in severe, early-onset COPD. Eur Respir J. 2007;30(6):1124–30.PubMedCrossRef

57.

Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest. 2008;133(3):767–74.PubMedCrossRef

58.

Rubins JB, Puri AK, Loch J, et al. Magnitude, duration, quality and function of pneumococcal vaccine responses in elderly adults. J Infect Dis. 1998;178(2):431–40.PubMedCrossRef

59.

Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 1999;29(2):281–8.PubMedCrossRef

60.

Poole P, Chacko EE, Wood-Baker R, et al. Influenzae vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;25(1):CD002733.

61.

Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004;173(1):673–81.PubMed

62.

World Health Organisation. WHO position paper on Haemophilus influenza type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record.). Wkly Epidemiol Rec. 2006;81(47):445–52.

63.

McElhaney JE. The unmet need in the elderly: designing new influenza vaccines for older adults. Vaccine. 2005;23(Suppl 1):S10–25.PubMedCrossRef

64.

Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2011;38(6):1250–1.PubMedCrossRef

65.

Itkin IH, Menzel ML. The use of marolide antibiotic substances in the treatment of asthma. J Allergy. 1970;45(3):146–62.PubMedCrossRef

66.

Kudoh S, Uetake T, Hagiwara K. et al Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis [in Japanese with English abstract]. Jpn J Thorac Dis. 1987;25:632–42.

67.

Tateda K, Ishii Y, Kimura S, et al. Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: a promising strategy or an oriental mystery? J Infect Chemother. 2007;13(6):357–67.PubMedCrossRef

68.

Smith DJ, Chang AB, Bell SC. Anti-inflammatory therapies in bronchiectasis. Eur Respir Mon. 2011;52:223–38.CrossRef

69.

Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004;125(2 Suppl):41S–50S.PubMedCrossRef

70.

Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurithromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol. 2001;25(4):492–9.PubMedCrossRef

71.

Cymbala AA, Edmonds LC, Bauer MA, et al. The disease modifying effects of twice weekly azithromycin in patients with bronchiectasis. Treat Respir Med. 2005;4(2):117–22.PubMedCrossRef

72.

Tsang KW, Ho PI, Chan KN. A pilot study of low dose erythromycin in bronchiectasis. Eur Respir J. 1999;13(2):361–4.PubMedCrossRef

73.

Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.PubMedCrossRef

74.

Basyigit I, Yildiz F, Ozkara SK, et al. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother. 2004;38(9):1400–5.PubMedCrossRef

75.

Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139–47.PubMedCrossRef

76.

Sapey E, Stockley RA. COPD exacerbations 2: aetiology. Thorax. 2006;61(3):250–8.PubMedCrossRef

77.

El Moussari R, Roede BM, Speelman P, et al. Short course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008;63(5):415–22.CrossRef

78.

Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character and severity of COPD exacerbations. Thorax. 2002;57(9):759–64.PubMedCrossRef

79.

Gursel G. Does coexistence with bronchiectasis influence intensive care unit outcome in patients with chronic obstructive pulmonary disease? Heart Lung. 2006;35(1):58–65.PubMedCrossRef

Titel: Bronchiectasis in Older Patients with Chronic Obstructive Pulmonary Disease
Prevalence, Diagnosis and Therapeutic Management
verfasst von: Deborah Whitters
Robert A. Stockley
Publikationsdatum: 01.04.2013
Verlag: Springer International Publishing AG
Erschienen in: Drugs & Aging / Ausgabe 4/2013
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-013-0053-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Bronchiectasis in Older Patients with Chronic Obstructive Pulmonary Disease

Prevalence, Diagnosis and Therapeutic Management

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Improving the Quality of Pharmacotherapy in Elderly Primary Care Patients Through Medication Reviews: A Randomised Controlled Study

Information for Adequate Prescribing to Older Patients

Association Between Prescribing of Cardiovascular and Psychotropic Medications and Hospital Admission for Falls or Fractures

Safety and Efficacy of Thrombolysis with Intravenous Alteplase in Older Stroke Patients

Do Statins Have a Role in the Prevention of Age-Related Macular Degeneration?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin